Answers are grounded in this paper and cite their sources.
AIM: To compare expected hospital costs and catheter-related outcomes of midline catheters (MCs) and long peripheral catheters (LPCs) for intravenous therapy lasting more than seven days. METHODS: A 7-28-day competing-risks renewal model assumed management and replacement after each failure. Inputs were pooled cause-specific complication rates from a systematic review of 5,023 MCs (129,179 catheter-days) and 962 LPCs (11,147 catheter-days). Uncertainty was quantified with 50,000 second-order probabilistic draws (95% credible intervals, CrI). Scenarios addressed between-study heterogeneity, outcome-specific denominators, and confounding by indication. Sensitivity analyses used re-extracted all-cause failure rates and four direct comparisons. RESULTS: At 14 and 28 days, incremental costs (MC minus LPC) were -€97.9 (95% CrI, -264 to + 21) and -€218.3 (95% CrI, -547 to +14) per patient, respectively. MCs were cost-saving in 93.9% and 96.6% of simulations, respectively. The higher MC insertion cost was offset after 2.6 days. At 14 days, expected failures per patient were 0.064 versus 0.246, and first-device therapy completion was 93.8% versus 78.2% (MC versus LPC). Bloodstream infection and symptomatic thrombosis accounted for 68.2% of the cost difference and 7.9% of the failure difference. All-cause failure rates yielded a 14-day cost difference of -€104.9. With head-to-head evidence, the LPC-to-MC failure rate ratio was 1.97 versus 4.89 using pooled rates, and the 14-day cost difference was -€60.9 (95% CrI, -226 to +54). Without the modeled excess of these complications with LPCs, MCs cost €17.6 more per patient. LIMITATIONS: Pooled observational data had unequal exposure across devices and were susceptible to confounding by indication. Costs reflected one national setting. The model excluded indirect costs, quality of life, and patient heterogeneity. CONCLUSIONS: MCs had fewer modeled failures across analyses. Estimated savings diminished with head-to-head evidence and depended on unconfirmed differences in major complications. Adjusted head-to-head studies are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Giustivi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: